Latest Conference Coverage

The multiple sclerosis fellow at Michigan Institute for Neurologic Disorders provided perspective on the clinical utility and advantages of a multi-protein test that assesses multiple sclerosis disease activity. [WATCH TIME: 3 minutes]

Secondary findings from a phase 3 study demonstrate a significant decrease in new T1 enhancing lesions and new enlarging hyperintense T2 lesions in patients with multiple sclerosis undergoing glatiramer acetate depot treatment.

Study results suggest that selected interventions should be based on phenotypic differences and treatment goals.

Non-Hispanic Black and Hispanic or Latino individuals on ocrelizumab did not demonstrate significantly greater risk on 24-week confirmed disability progression relative to non-Hispanic Whites.

Majority of patients with relapsing multiple sclerosis demonstrated achieving and maintaining no evidence disease activity after being treated with ublituximab.

The director of Cleveland Clinic’s Cerebrovascular Center provided clinical perspective on the treatment decisions mobile stroke units face, and whether directly transferring patients to angiography suite is necessary.

Daniel Ontaneda, MD, program committee vice-chair of ACTRIMS, provided insight on the notable sessions and themes clinicians should pay attention to at this year’s forum, which takes place February 23-25, in San Diego, California.

As a recap from ISC 2023, get caught up on some of the latest news in stroke as the NeurologyLive® team shares some of our data updates and expert insights.

The vascular and interventional neurologist at Cleveland Clinic provided insight on a study presented at the 2023 International Stroke Conference that observed the clinical effectiveness of mechanical thrombectomy beyond 24 hours. [WATCH TIME: 6 minutes]

The director of Cleveland Clinic’s Cerebrovascular Center discussed the decisions mobile stroke units face and why opting for direct transfer to angiography is meant for certain scenarios. [WATCH TIME: 3 minutes]

The director of Cleveland Clinic’s Cerebrovascular Center provided perspective on a new study presented at the International Stroke Conference on experiences of poststroke patients taken directly to angiography suite. [WATCH TIME: 3 minutes]

Investigators Macarena Hernandez, PhD, and Marc Ribo, MD, provided commentary on positive phase 2a findings assessing ApTOLL in combination with EVT in patients with ischemic stroke.

Blood pressure medications may not be safe or effective to use for lowering systolic blood pressure following endovascular treatment for acute ischemic stroke.

The professor of neurology at Harvard Medical School spoke at the 2023 ISC Conference about highlights from the STROKE-AF study after a 3-year follow-up. [WATCH TIME: 5 minutes]

In comparison with those who underwent additional imaging, patients with large vessel occlusion who directly went to angiography suite had higher mortality, but with no difference in functional outcome.

At the conclusion of the trial, treatment with 0.2 mg/kg of ApTOLL with EVT resulted in reduced brain edema and hemorrhagic transformation, as well as fewer deaths than placebo and 0.05 mg groups.

Patients with noncardioembolic ischemic stroke do not typically monitor post-stroke longterm to detect atrial fibrillation although findings from a trial follow-up suggest otherwise.

The medical director of stroke at Fairview Hospital, an affiliate of Cleveland Clinic, provided perspective on a new intervention that improves communication and reduces hospital readmission for stroke.

The chief medical officer at Alzheon provided perspective on the next steps for ALZ-801 following a successful phase 2 study of patients with APOE ε4/4 or APOE ε3/4 genotype. [WATCH TIME: 2 minutes]

At the 2022 AES Conference, the Baldwin Keyes professor of neurology at Thomas Jefferson University talked about how clinicians and patients might define a seizure. [WATCH TIME: 3 minutes]

At the 2022 AES Conference, the Baldwin Keyes professor of neurology at Thomas Jefferson University, talked about what defines a ‘seizure’ and changing the terminology. [WATCH TIME: 5 minutes]

At the 2022 AES Conference, the head of neurosciences at the Jane and John Justin Neurosciences Center of Cook Children’s Medical Center, talked about epilepsy surgery as an alternative for some patients. [WATCH TIME: 5 minutes]

The assistant professor in the Department of Neurology at the University of Wisconsin spoke about healthcare providers establishing trust with their patients and improving health equity. [WATCH TIME: 3 minutes]

The scientific researcher and clinical manager, Icahn School of Medicine at Mount Sinai, spoke about the clinical models used to predict seizures in poststroke patients. [WATCH TIME: 4 minutes]

At the 2022 AES annual meeting, the associate professor at Harvard Medical School and neurologist at the Brigham and Women's Hospital talked about seizure frequency and insomnia. [WATCH TIME: 2 minutes]

At the 2022 AES Conference, the scientific researcher and clinical manager at the Icahn School of Medicine at Mount Sinai talked on seizure management with medication in poststroke patients. [WATCH TIME: 3 minutes]

Susan Abushakra, MD, chief medical officer at Alzheon, provided insight on findings from a phase 2 study in which ALZ-801 showed beneficial effects on cognition, Aß 42/40, and brain atrophy.

The assistant professor of neurology at the University of Virginia spoke at the 2022 AES Conference about clinical outcomes of patients with dementia who experience seizures. [WATCH TIME: 5 minutes]